Cytek Biosciences, Inc. (CTKB) Q2 2026 Earnings Call Transcript

Cytek Biosciences NASDAQ: CTKB reported second-quarter 2026 revenue growth of 6% year over year, sup

Cytek Biosciences, Inc. (CTKB) came out with a quarterly loss of $0.05 per share versus the Zacks Co

Cytek Biosciences (NASDAQ:CTKB) reported quarterly losses of $(0.09) per share which met the analyst

Cytek Biosciences (NASDAQ:CTKB) raises FY2026 sales outlook from $205.000 million-$212.000 million t

FREMONT, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “

Cytek Biosciences (CTKB) doesn't possess the right combination of the two key ingredients for a like

Champions Oncology and Cytek Biosciences have different growth drivers and valuations, but which lif

FREMONT, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “

US stock futures higher with Nasdaq 100 up 150 points. Ryanair (RYAAY) shares fall after weak Q1 res

FREMONT, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Spectral flow cytometry leader Cytek Biosciences,

FREMONT, Calif., June 10, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading

US stock futures higher, Nasdaq futures down. Concrete Pumping Holdings shares up 28.94% pre-market.

At CYTO 2026, Cytek will showcase its cell analysis solutions, including the public debut of a new 7

US stock futures lower, Braze Inc (BRZE) shares drop 8.4% in pre-market trading after reporting mixe

Phreesia (NYSE: PHR) shares rose in pre-market trading after better-than-expected sales results. Oth

Stephens & Co. analyst Mason Carrico maintains Cytek Biosciences (NASDAQ:CTKB) with a Overwei

Morgan Stanley analyst Tejas Savant maintains Cytek Biosciences (NASDAQ:CTKB) with a Equal-Weight

Cytek Biosciences, Inc. (CTKB) Q1 2026 Earnings Call Transcript

Cytek Biosciences, Inc. (CTKB) came out with a quarterly loss of $0.12 per share versus the Zacks Co

Cytek Biosciences (NASDAQ:CTKB) affirms FY2026 sales outlook from $205.000 million-$212.000 million

Cytek Biosciences (NASDAQ:CTKB) reported quarterly losses of $(0.15) per share which missed the anal

FREMONT, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “C

Cytek Biosciences, Inc. (NASDAQ: CTKB - Get Free Report) has been assigned an average recommendation

FREMONT, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or

Cytek Biosciences celebrates one year of operations at its Singapore facility, which has enhanced Cy

Cytek Biosciences (NASDAQ: CTKB) outlined its recent product launches, geographic diversification, a

Cytek Biosciences, Inc. (CTKB) came out with a quarterly loss of $0.01 per share versus the Zacks Co

Cytek Biosciences, Inc. (CTKB) Q4 2025 Earnings Call Transcript

Cytek Biosciences (NASDAQ:CTKB) sees FY2026 sales of $205.000 million-$212.000 million vs $207.058 m

Cytek Biosciences (NASDAQ:CTKB) reported quarterly losses of $(0.34) per share which missed the anal

FREMONT, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or

Cytek Biosciences, Inc. (NASDAQ: CTKB), a leading cell analysis solutions company, today announced p

TD Cowen analyst Brendan Smith maintains Cytek Biosciences (NASDAQ:CTKB) with a Buy and raises th

Piper Sandler analyst David Westenberg maintains Cytek Biosciences (NASDAQ:CTKB) with a Overweigh

Cytek Biosciences (NASDAQ:CTKB) affirms FY2025 sales outlook from $196.000 million-$205.000 million

Cytek Biosciences (NASDAQ:CTKB) reported quarterly losses of $(0.04) per share which beat the analys

FREMONT, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- In a move that strengthens its European operation

Cytek Biosciences (NASDAQ:CTKB) narrows FY2025 sales outlook from $196.000 million-$210.000 million

Cytek Biosciences (NASDAQ:CTKB) reported quarterly losses of $(0.04) per share which met the analyst

Morgan Stanley analyst Tejas Savant maintains Cytek Biosciences (NASDAQ:CTKB) with a Equal-Weight